Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
This phase II trial studies the side effects of chemotherapy and intensity modulated
radiation therapy in treating patients with low-risk HIV-associated anal cancer, and
nivolumab after standard of care chemotherapy and radiation therapy in treating patients with
...
Age: 18 years - 66+
Gender: All
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Added to Radiation or Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
This phase II trial studies the effect of pembrolizumab in combination with radiation therapy
or pembrolizumab alone compared to the usual approach (chemotherapy plus radiation therapy)
after surgery in treating patients with head and neck squamous cell carcinoma th...
Age: 18 - 79 years
Gender: All
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus
atezolizumab compared with placebo in participants with unresectable esophageal squamous cell
carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers h...
Age: 18 years - 66+
Gender: All
Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma
The purpose of this research study is to investigate a shorter radiation treatment schedule
for head and neck cancers in patients 70 years of age and older.
Standard radiation treatment for head and neck patients normally requires that the patient
travel to the ...
Age: 70 years - 66+
Gender: All
A Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a Phase 1b, open-label dose escalation trial of ATRC-101, an engineered fully
human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human
antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will...
Age: 18 years - 66+
Gender: All
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
This is an First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of
HB-201 single vector therapy and HB-201 & HB-202 two-vector therapy in patients with HPV 16+
confirmed cancers comprising two parts: Phase I Dose Escalation and Phase II Dose...
Age: 18 years - 66+
Gender: All
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation)
therapy works in comparison to standard-dose chemoradiation in treating patients with
early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, a...
Age: 18 years - 66+
Gender: All
Vaccination With Flt3L, Radiation, and Poly-ICLC
This is a combination of 4 therapies, three of which are used to treat a single "target site"
of your cancer (such as a lymph node or a single tumor), and the 4th is given directly into
the blood stream (intravenous or "IV").
1. Radiation: The target site --lymph nod...
Age: 18 years - 66+
Gender: All
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
This will be a blinded, placebo-controlled, randomized, phase 2 study in which subjects will
be randomly assigned 1:1 to cemiplimab plus placebo or cemiplimab plus ISA101b.
Age: 18 years - 66+
Gender: All
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
This is a phase 3 randomized, placebo controlled study to evaluate the safety and anti-tumor
activity of Avelumab in combination with standard of care chemoradiation (SoC CRT) versus SoC
CRT alone in front-line treatment of patients with locally advanced head and neck...
Age: 18 years - 66+
Gender: All
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
This randomized phase III trial studies radiation therapy and cisplatin with triapine to see
how well they work compared to the standard radiation therapy and cisplatin alone in treating
patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or sta...
Age: 18 years - 66+
Gender: Female
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA
non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in
a patient's tumor cells may help doctors select the best treatment for patients that h...
Age: 18 years - 66+
Gender: All
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
This phase II/III trial studies how well radiation therapy works when given together with
cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with
high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squ...
Age: 18 years - 66+
Gender: All
Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of
an investigational drug. Phase I studies also try to define the appropriate dose of the
investigational drug to use for further studies. "Investigational" means that the drug i...
Age: 18 years - 66+
Gender: All